From award-winning innovation to a proven diagnostic product
Llusern has progressed from early innovation in antimicrobial resistance diagnostics to a market-facing product focused on rapid molecular UTI testing.
Today
Lodestar in daily use within private urology clinics and in NHS evaluations across the UK.
2026
Abstracts presented at the European Association of Urology and at the American Urological Association annual congresses.
2025
ISO 13485 certification achieved. Study in elderly care settings to reduce antibiotic use. First sales into private urology practices.
2024
Llusern opens dedicated production lab. Lodestar UTI testing system UKCA marked. Two peer-reviewed publications in JAC-AMR. Llusern runner-up in the Longitude Prize on AMR.
2023
Lodestar DX included in NICE Early Value Assessment. Llusern opens first office and lab at Cardiff Edge.
2022
Dr Emma Hayhurst receives Innovate UK’s Women in Innovation Award.
2020
Llusern Scientific Limited spun-out from University of South Wales.
2016
Dr Emma Hayhurst and Dr Jeroen Nieuwland win a Nesta Discovery Award to research affordable diagnostic technology that will impact AMR.
Start a conversation with Llusern
Llusern is developing treatment-directing diagnostics for high-volume healthcare challenges, starting with rapid molecular UTI testing. To learn more about the company, the product and the opportunity ahead, speak to the Llusern team.